Recent Updates
Recently added Catalysts
SGMT

Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640

Wednesday, June 17, 2020 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+110%
120-day peak, hindsight
Typical move
5.7%
average across 12 past catalysts
Cash runway
~69 mo
Minimal dilution risk
Lead asset
TVB-2640
Phase 2 · Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

Full Press Release Details

Sagimet Announces Positive Topline Results in 12-week NASH Phase 2 Clinical Trial of FASN Inhibitor TVB-2640.
ShareAdd on Google
Tags: SGMT Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jun 17, 2020

Biotech snapshot

Cash runway
$258M liquidity · $4M/mo burn
~69 mo
Minimal dilution risk
Lead asset
TVB-2640Phase 2
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease →

Catalyst track record

+110%
best trade around SGMT's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for SGMT.

See every catalyst's timing & PoA →